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b cell failure in type 2 diabetes (T2D) is associated
with hyperglycemia, but the mechanisms are
not fully understood. Congenital hyperinsulinism
caused by glucokinase mutations (GCK-CHI) is
associated with b cell replication and apoptosis.
Here, we show that genetic activation of b cell
glucokinase, initially triggering replication, causes
apoptosis associated with DNA double-strand
breaks and activation of the tumor suppressor
p53. ATP-sensitive potassium channels (KATP
channels) and calcineurin mediate this toxic
effect. Toxicity of long-term glucokinase over-
activity was confirmed by finding late-onset dia-
betes in older members of a GCK-CHI family.
Glucagon-like peptide-1 (GLP-1) mimetic treatment
or p53 deletion rescues b cells from glucokinase-
induced death, but only GLP-1 analog rescues
b cell function. DNA damage and p53 activity in
T2D suggest shared mechanisms of b cell failure
in hyperglycemia and CHI. Our results reveal
membrane depolarization via KATP channels, calci-
neurin signaling, DNA breaks, and p53 as determi-
nants of b cell glucotoxicity and suggest pharmaco-
logical approaches to enhance b cell survival in
diabetes.CellINTRODUCTION
Clinical and experimental data suggest that the pathogenesis of
type 2 diabetes (T2D) involves an initial phase of adaptation to
insulin resistance in which pancreatic b cells increase insulin
secretion and mass. This is followed by a decompensation
phase, where glucose homeostasis is disrupted due to b cell
dysfunction and potentially b cell death, resulting in hypergly-
cemia and relative hypoinsulinemia (Butler et al., 2003; Weir
et al., 2001). Glucose is thought to play a key role in both phases,
initially boosting insulin secretion and b cell replication and later
fueling a vicious cycle of glucotoxicity that precipitates b cell
failure and hyperglycemia (Bensellam et al., 2012; Chang-Chen
et al., 2008; Weir et al., 2001). However, the mechanisms
accounting for this dual effect are not fully understood. Oxidative
stress, associated with increased metabolic activity, has been
proposed as the driving force behind glucotoxicity (Guo et al.,
2013; Poitout and Robertson, 2008); endoplasmic reticulum
(ER) stress and failure of autophagy have also been implicated
(Karunakaran et al., 2012; Las and Shirihai, 2010).
Congenital hyperinsulinism (CHI) is a rare monogenic disease
with clinical manifestations opposite to diabetes (hyperinsuline-
mic hypoglycemia), resulting from mutations in key genes
controlling insulin secretion. Most commonly, it results from
loss-of-function mutations in the Kir6.2 and Sur1 subunits of
the ATP-sensitive potassium channel (KATP channel), encoded
by KCNJ11 and ABCC8, respectively. These cause permanent
b cell membrane depolarization and, consequently, hypersecre-
tion of insulin (James et al., 2009). Gain-of-function mutations inMetabolism 19, 109–121, January 7, 2014 ª2014 Elsevier Inc. 109
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DNA Damage and p53 in b Cell Glucotoxicityglucokinase (GCK-CHI), the first step in glycolysis, also cause
excessive insulin secretion, leading to life-threatening hypogly-
cemia (Cuesta-Mun˜oz et al., 2004; Glaser et al., 1998; Kassem
et al., 2010). We and others have recently shown that islets of
GCK-CHI patients are larger than normal (Cuesta-Mun˜oz et al.,
2004; Kassem et al., 2010). In contrast, CHI patients with inacti-
vating mutations in KCNJ11 or ABCC8 either have small, poorly
formed islets scattered throughout the pancreas (diffuse CHI), or
a well-defined, monoclonal lesion characterized as adenoma-
tous hyperplasia (focal CHI) (Rahier et al., 2011). In all cases,
affected b cells show increased proliferation (Kassem et al.,
2000, 2010). These observations, combined with genetic and
pharmacologic manipulations of GCK and KATP channels in
mice, have highlighted the central role of glycolysis and mem-
brane depolarization in homeostatic b cell replication and its
potential utility for regenerative therapy in diabetes (Porat
et al., 2011). However, the islets of CHI patients also contain
increased numbers of apoptotic b cells, showing that glucose
metabolism and membrane depolarization can simultaneously
exert both mitogenic and toxic effects on human b cells (Kassem
et al., 2000, 2010).
To better understand how glycolysis controls b cell fate in vivo,
we generated a transgenic mouse model of GCK-CHI. Here, we
describe the insights gained from this model on the mechanisms
of b cell glucotoxicity and corroborate these findings in a mouse
model of diabetes and in tissues from human T2D and CHI
patients.
RESULTS
Acute Induction of GCK Causes Fasting Hypoglycemia
and Hyperinsulinemia
A GCK transgene containing a strong activating mutation found
in a GCK-CHI patient (Y214C) (Cuesta-Mun˜oz et al., 2004) was
inserted into the Rosa26 locus in embryonic stem cells (ESCs),
downstream of a loxP-flanked transcriptional stop cassette (Sri-
nivas et al., 2001), and followed by an internal ribosome entry site
(IRES)-EGFP reporter (Murtaugh et al., 2003). Mice generated
from these cells (mutGCK) were crossed either with Pdx1-CreER
mice (Gu et al., 2002) to allow for acute, tamoxifen-induced
activation of the transgene in adult b cells (Pdx1-GCK) or with
insulin-Cre mice (Gannon et al., 2000) to force expression of
mutant GCK in b cells as they form in the embryo (ins-GCK)
(Figure 1A).
Islets isolated 3 days after injection of adult Pdx1-GCK mice
with tamoxifen showed a 50% increase in the level of GCK
mRNA, indicating expression of the transgene (Figure 1B).
Expression of the mutated GCK transgene is expected to
enhance glucose utilization and the generation of ATP and,
consequently, to boost insulin secretion and reduce blood
glucose. Because of the kinetic characteristics of native and
mutant GCK, the largest effect is expected at low glucose levels
in which the enzymatic activity of native GCK is negligible.
Accordingly, a near doubling of oxygen consumption was
observed in transgenic islets incubated in 2 mM glucose (Fig-
ure 1C). Activation of the transgene resulted in moderate fasting
hypoglycemia 3 days after gene induction (Figure 1D, left). As ex-
pected from this model of insulin dysregulation, absolute fasting
plasma insulin levels were only slightly (but significantly) higher110 Cell Metabolism 19, 109–121, January 7, 2014 ª2014 Elsevier Inthan those in control mice (Figure 1D, middle). However, the
insulin/glucose ratio, a measure of b cell responsiveness to
ambient glucose levels, wasmarkedly elevated (Figure 1D, right).
Consistent with observations in human GCK-CHI (Kassem
et al., 2010) andmice injectedwith a small-molecule glucokinase
activator (Porat et al., 2011), the fraction of b cells engaged in the
cell cycle doubled 2 days after transgene activation, as mea-
sured by immunostaining and qRT-PCR for cell cycle markers
(Figure 1E). Thus, this animal model provides a tool to study
the effect of controlled, increased b cell glycolysis without the
confounding effects of ambient hyperglycemia.
Prolonged Activation of mutGCK Transgene Causes
b Cell Dysfunction and Death
As expected, activation of the transgene resulted in a rapid and
significant decrease in random blood glucose levels (Figure 1F,
inset). Surprisingly, however, this decrease was short lived,
reaching a nadir at 4 days before returning to normal 1 week after
transgene activation (Figure 1F). To determine the reason for
this, we quantified the fraction of b cells that expressed the trans-
gene strongly, using EGFP as a surrogate marker. At 3 days after
tamoxifen injection, 25% of b cells stained for EGFP, reflecting
mosaic transgene expression; 22 days after tamoxifen injection,
only 5% stained positive (Figure 2A). Since Cre-mediated trans-
gene activation is irreversible, disappearance of EGFP+ cells
suggested that they were gradually eliminated.
To examine this more directly, we stained histological sections
for apoptosis. As shown in Figure 2B, islets of transgenic mice
had abundant TUNEL+ b cells compared with minimal staining
in control littermates. Furthermore, by day 4 after induction,
the fraction of replicating EGFP+ b cells (measured by Ki67
staining) was only 0.34%, compared with 1.29% of b cells in
wild-type mice and 1.83% of EGFP b cells in Pdx1-GCK mice
(Figure 2C). These findings suggest that after a few days of activ-
ity, transgene-expressing b cells stop proliferating and are later
eliminated.
b Cell Apoptosis and Late Development of Diabetes in
Human GCK-CHI
The findings above show that expression of active GCK inmouse
b cells is both mitogenic and toxic. A similar phenomenon
of b cell mitogenicity accompanied by apoptosis, and eventually
b cell failure and diabetes, was seen in human KATP-CHI (Kassem
et al., 2000). However, in the case of human GCK-CHI, b cell
apoptosis was documented in only a single patient so far (Kas-
sem et al., 2010), and no data are available on the long-term
outcome of patients. To determine if excessive b cell apoptosis
is a general feature of GCK-CHI, we stained archived material
from three previously reported patients carrying different muta-
tions in GCK (pA454 dup andW99L) who underwent pancreatec-
tomy due to uncontrolled hypoglycemia at ages 2–7 years
(Sayed et al., 2009; Snider et al., 2013). Strikingly, all three cases
showed b cell apoptosis (TUNEL+ insulin+ cells) in 0.59%–1.16%
of b cells, whereas in 4 controls aged 10 months to 7.8 years,
TUNEL+ b cells were rarely seen (Figure S1 available online).
Apoptosis was more prominent in the two patients with the
more severe mutation (pA454 dup).
If b cell apoptosis increases, as shown by Kassem et al. (2010)
and above, one would expect GCK-CHI patients to enter clinicalc.
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Figure 1. A Mouse Model for GCK-CHI
(A) Schematic of the transgenic construct. Cre
activation causes permanent expression of
GCK-Y214C and EGFP tag driven by an internal
ribosome entry site (IRES). Cell and temporal
specificity is determined by the Cre-expressing
transgene used.
(B) Expression level of GCK in islets isolated
from Pdx1-GCK mice 3 days after tamoxifen-
induced expression of the transgene by quan-
titative RT-PCR. GCK levels (including both
endogenous and transgenic) were normalized to
b-actin. n = 5 mice/group. Control mice were
single transgenic littermates carrying either the
GCK or Cre transgene.
(C) Increased oxygen consumption in islets
isolated from Pdx1-GCK mice 2 days after
tamoxifen-induced transgene expression and
incubated at 2 mM glucose. n = 10 control and
9 mutGCK mice. OCR, oxygen consumption
rate.
(D) Fasting hypoglycemia (left), fasting hyper-
insulinemia (center), and increased insulin/
glucose ratio (right; ratio 3 100) in 5-week-old
Pdx1-GCK mice 3 days after tamoxifen injection.
n = 12 control and 11 Pdx1-GCK mice.
(E) The fraction of replicating b cells doubled in
Pdx1-GCK mice 2 days after transgene induc-
tion. Left: quantification of Ki67+ insulin+ cells in
paraffin sections. n = 6–8 mice/group, >2,000
b cells counted/mouse. Right: qRT-PCR for cell
cycle markers on RNA extracted from islets
2 days after tamoxifen injection. n = 4 mice/
group.
(F) Hypoglycemia after induction of Pdx1-GCK
transgene is transient. Tamoxifen was injected at
day 0. n = 21 Pdx1-GCK and 12 control mice. In
each time point, at least 5 mice/group were
measured.
Data are represented as mean ± SE.
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DNA Damage and p53 in b Cell Glucotoxicityremission (cessation of hypoglycemic episodes) and perhaps
even develop diabetes over time. We contacted one previously
reported GCK-CHI family (Glaser et al., 1998) and found that of
five mutation carriers, one was diagnosed with insulin-requiring
diabetes at age 48, as reported in the original publication; the
proband had diabetes diagnosed at age 39 and is currently
treated with oral medications; his sister died of breast cancer
at age 49 without diabetes; and the proband’s son has had
metformin-treated diabetes since age 28 (BMI 26.6); whereas
the proband’s daughter’s hypoglycemia remitted at age 14
(currently euglycemic; BMI 30.7). Thus, three of the four living
mutation carriers developed diabetes, and one is in remission,
suggesting reduced b cell function. The deterioration of b cell
function over time may not occur in all families or all mutations,
and a systematic review is needed to fully define the long-term
effect of activating GCK mutations in man.
In summary, evidence from human GCK-CHI indicates exten-
sive b cell apoptosis giving rise with time to b cell failure and
diabetes. This conclusion is consistent with the phenotype ofCellPdx1-GCK mice, even though the time to b cell failure is dramat-
ically shorter in the mouse model (days versus years).
Molecular Characterization of b Cell Glucotoxicity
To understand the basis of the observed toxicity of active GCK,
we examined the expression of multiple markers of b cell identity
and stress after tamoxifen-induced expression of mutant GCK in
adult Pdx1-GCK mice. Staining for the key b cell transcription
factors MafA and Nkx6.1, but not Pdx1, was dramatically
reduced, as shown to occur in high glucose levels in vitro (Kaneto
et al., 2008; Weir et al., 2001) and in mouse and human T2D (Guo
et al., 2013) (Figure S2). In addition, we stained for the ER, oxida-
tive, or genotoxic stress marker Chop (also known as Gadd153
or Ddit3). Approximately 0.6%of cells in transgenic islets stained
for Chop compared with none in wild-type littermates (Figure 3A,
left andmiddle panels). Consistent with these findings, qRT-PCR
analysis revealed increased expression of Chop mRNA (Fig-
ure 3A, right). Atf3, another ER and oxidative stress marker
(Eizirik et al., 2008), was also markedly elevated in Pdx1-GCKMetabolism 19, 109–121, January 7, 2014 ª2014 Elsevier Inc. 111
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Figure 2. Apoptosis and Reduced Prolifera-
tion of b Cells following Expression of
Active GCK
(A) Gradual loss of cells expressing high levels of
GFP in Pdx1-GCKmice. Upper panel, 3 days after
tamoxifen; n = 5 mice. Lower panel, 22 days; n = 4
mice. Scale bars: 20 mm (here and in all figures
except Figure 5B). Quantification of GFP+ b cells at
days 3 and 22 is on the right.
(B) TUNEL staining showing apoptosis of Pdx1-
GCK b cells and quantification. Highmagnification
in the lower panels demonstrates insulin staining
of TUNEL+ cells. Pdx1-GCK mice were injected
with tamoxifen 4 days prior to sacrifice. n = 4–5
mice/group.
(C) Reduced replication of GFP+ b cells compared
with control and GFP cells 4 days after tamoxifen
injection to Pdx1-GCK mice. n = 12 Pdx1-GCK
and 8 control mice.
Data are represented as mean ± SE. See also
Figure S1.
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DNA Damage and p53 in b Cell Glucotoxicityislets (Figure 3A, right), whereas the levels of spliced Xbp1, a
more specific marker of ER stress, were unchanged (Figure 3A,
right panel). This suggests that the cause of elevated Chop and
Atf3 is oxidative or genotoxic stress, consistent with the idea that
oxidative stress is a major determinant of b cell failure in T2D
(Guo et al., 2013).
Oxidative stress was previously shown to cause double-
strand DNA breaks (Cadet et al., 2012). Strikingly, 13.8% of
b cell nuclei in transgenic mice contained foci stained for
53BP1, a protein recruited to sites of double-strand breaks in
DNA (Schultz et al., 2000), compared with only 1.2% in controls
(Figure 3B). Consistently, 1.75% of nuclei in transgenic islets
stained for gH2AX, a histone variant marking chromatin areas
flanking double-strand DNA breaks (Rogakou et al., 1998),
compared with only 0.2% in controls (Figure 3C). Increased
gH2AX was also seen in islets that were isolated from Pdx1-
GCKmice after tamoxifen injection and cultured for 3 days, sup-
porting the cell-autonomous nature of the effect (Figure S3). To
determine whether the presence of DNA damage is specific to
this mouse model, we examined pancreatic sections from a
patient with an activating GCK mutation (V91L, different than112 Cell Metabolism 19, 109–121, January 7, 2014 ª2014 Elsevier Inc.the mutation used in our transgenic
mice) (Kassem et al., 2010). Abundant
gH2AX-stained b cells were seen in islets
of this patient, compared with no gH2AX
staining in age-matched controls. This
confirms relevance in man and indicates
that DNA damage results from increased
GCK activity and is not a consequence of
a specific GCK mutation (Figure 3D).
DNA damage typically results in activa-
tion of the tumor suppressor p53, which
may induce cell-cycle arrest and a DNA
damage response or trigger programmed
cell death (Halazonetis et al., 2008). Strik-
ingly, 2.3% of the nuclei in Pdx1-GCK
islets stained positive for p53, compared
with 0.4% in controls (Figure 3E).These findings suggest that excessive glucose metabolism in
b cells leads, perhaps via oxidative stress and reactive oxygen
species (ROS), to double-strand breaks in the DNA, activation
of p53, and apoptosis. We next studied the signaling pathway
leading from glycolysis to DNA damage.
b Cell Membrane Depolarization Is Necessary and
Sufficient to Trigger DNA Damage
Increased glucose metabolism in b cells results in increased
mitochondrial ATP production. In the insulin secretion pathway,
this causes the closure of KATP channels, membrane depolariza-
tion, elevated intracellular calcium concentrations, and ulti-
mately insulin exocytosis. To study how expression of mutant
GCK results in b cell DNA damage, we asked if increased glycol-
ysis acted through membrane depolarization as in insulin secre-
tion. We utilized transgenic mice expressing a Cre-inducible
constitutively active mutant of Kir6.2, a subunit of the b cell
KATP channel. Expression of the Kir6.2-V59M mutation in b cells
prevents membrane depolarization and, consequently, blocks
glucose-stimulated insulin secretion and causes diabetes (Gir-
ard et al., 2009). Acute expression of the Kir6.2 transgene was
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Figure 3. Molecular Markers of b Cell Glu-
cotoxicity in Mice and Humans
(A) Left: immunostaining for the stress marker
Chop in islets of control and Pdx1-GCK mice
4 days after tamoxifen injection. Right: qRT-PCR
analysis of Chop and Atf3 (normalized to b-actin)
and spliced Xbp1 (normalized to total Xbp1) in
RNA from Pdx1-GCK islets 3 days after tamoxifen
injection. n = 5 mice/group. Arrows point to Chop+
b cells.
(B) Staining for the DNA damage marker 53BP1 in
b cells of Pdx1-GCK mice 4 days after tamoxifen
injection. Right panel shows the frequency of
b cells containing nuclear foci of 53BP1. n = 6
mice/group, 1,800–2,700 cells counted/mouse.
Arrows point to 53BP1+ b cells.
(C) Staining and quantification for the DNA dam-
age marker gH2AX in b cells of control and Pdx1-
GCK mice 4 days after tamoxifen injection. n = 4
Pdx1-GCK and 3 control mice. There were 2,000–
3,500 cells counted/mouse. Arrows point to
gH2AX+ b cells.
(D) Staining for gH2AX in pancreatic sections from
a 36-month-old human GCK-CHI patient (V91L)
(Kassem et al., 2010). Arrows point to gH2AX+
b cells.
(E) Staining and quantification for p53 in islets of
control and Pdx1-GCK mice 4 days after tamox-
ifen injection. n = 3 control and 4 Pdx1-GCK mice.
Arrows point to p53+ islet cells.
Data are represented as mean ± SE. See also
Figures S2 and S3.
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DNA Damage and p53 in b Cell Glucotoxicityachieved by tamoxifen injection of adult Pdx1-CreER;Kir6.2-
V59M mice (Pdx1-Kir6.2). As expected, these mice rapidly
developed severe hyperglycemia (Figure 4A, left). Compound
transgenic mice coexpressing both Kir6.2-V59M and mutant
GCK in b cells (Pdx1-GCK;Kir6.2) were also hyperglycemic
(like Pdx1-Kir6.2 mice), reflecting the fact that membrane depo-
larization is necessary for insulin secretion downstream of GCK
(Figure 4A, left).
Strikingly, expression of Kir6.2-V59M reduced gH2AX staining
in b cells of Pdx1-GCK mice 4 days after tamoxifen injection
(Figure 4A, middle) and attenuated b cell apoptosis as judged
by TUNEL staining (Figure 4A, right). These results suggest
that membrane depolarization is necessary for glycolysis-
induced DNA double-strand breaks and apoptosis in b cells.
We then asked if membrane depolarization, in the absence of
increased glycolysis, is sufficient to cause DNA double-strand
breaks in b cells. We stained sections of pancreata resected
from patients with KATP-CHI, caused by mutations in either
ABCC8 or KCNJ11. Both gH2AX and 53BP1 staining were
observed in b cells of these CHI patients, but not in age-matchedCell Metabolism 19, 109–12controls (Figure 4B). To confirm that this
difference was due to the mutations and
not to other differences between patients
and controls, we examined gH2AX and
53BP1 in a patient with the focal form of
CHI. In this disease variant, the patient
inherits a single, recessive, inactivating
KATP channel gene mutation, and a sec-ond somatic mutation results in loss of the normal allele and
clonal expansion of b cells carrying only an inactivating KATP
channel mutation. This causes the formation of a discrete focal
lesion containing defective, hyperfunctioning b cells, whereas
b cells outside the lesion function normally (Glaser et al., 1999).
This allows comparison between defective and normal b cells
that were exposed to precisely the samemilieu prior to resection.
b cells within the focal lesion stained positive for gH2AX and had
53BP1 nuclear foci, whereas cells outside the lesion did not (Fig-
ure 4B). We have previously shown increased b cell apoptosis in
patients with both diffuse and focal CHI caused by the same
gene mutations (Kassem et al., 2000). These findings show
that b cell membrane depolarization is both necessary and suffi-
cient to cause the DNA damage response seen following GCK
activation.
Calcineurin Mediates b Cell Apoptosis Downstream of
Active GCK
In the insulin secretion pathway, membrane depolarization is
immediately followed by the opening of voltage-dependent1, January 7, 2014 ª2014 Elsevier Inc. 113
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Figure 4. Chronic Membrane Depolarization
and Calcineurin Mediate b Cell Glucotoxicity
(A) Analysis of Pdx1-GCKmice expressing a Kir6.2-
V59M mutation that prevents membrane depolari-
zation. Left: hyperglycemia develops in Pdx1-
Kir6.2 mice regardless of the presence or absence
of mutated GCK. Center: the Kir6.2-V59Mmutation
reduces DNA double-strand breaks in Pdx1-GCK
mice 4 days after tamoxifen injection. Right: the
Kir6.2-V59M mutation reduces b cell apoptosis in
Pdx1-GCK mice. n = 6–10 mice/group.
(B) Immunofluorescence detection of the DNA
damage response markers gH2AX and 53BP1 in
paraffin sections of human pancreas. Control: a
healthy individual (similar results were obtained at
1 or 3 months old). Kir6.2 diffuse: patient was
3 months old and homozygous for KCNJ11
p.(Tyr12*). Sur1 diffuse: patient was 6 months old
and homozygous for ABCC8 p.(Arg836*; similar
results were found for a patient aged 1 month that
was homozygous for the ABCC8 c.950 delC
mutation). Sur1 ‘‘focal’’ and ‘‘outside’’ refer to areas
within the same pancreas, inside a hyperplastic
focal lesion and outside it, in the normal adja-
cent pancreas (paternal heterozygous ABCC8
p.[Arg836*]; age 70 months). All patients and con-
trolswere previously reported (Kassemet al., 2000).
(C) Treatment of Pdx1-GCK mice with the calci-
neurin inhibitor tacrolimus (FK-506, FK) reduces
b cell apoptosis 4 days after tamoxifen injection.
n = 4–7 mice/group. Mice were injected with either
0.3 mg/kg or 1 mg/kg FK-506/day from the day of
tamoxifen injection to sacrifice. For each mouse,
2,300–8,000 b cells were counted.
Data are represented as mean ± SE.
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DNA Damage and p53 in b Cell Glucotoxicitycalcium channels (VDCCs). To ask if VDCCs mediate the toxic
effects of active GCK, we treated Pdx1-GCK mice with the
calcium channel blocker nifedipine. As expected, this led to
transient hyperglycemia due to blockade of insulin secretion.
However, histological examination of pancreata 4 days after
activation of the GCK transgene did not reveal a significant
decrease of b cell apoptosis or DNA damage (not shown). To
further examine how calcium signaling affects glucotoxicity,
we treated Pdx1-GCK mice with tacrolimus (FK-506), a selec-
tive inhibitor of calcineurin, a phosphatase activated by
calcium. As shown in Figure 4C, tacrolimus significantly reduced
b cell apoptosis, suggesting that calcium signaling via calci-
neurin activity is required for the toxic effects of glucose. The
source of the calcium (intra- or extracellular) and the identity of
the responsible calcium channel remain to be discovered.
Glucose-Induced b Cell Death, but Not Dysfunction, Is
Mediated through p53
Because oxidative stress can induce apoptosis through a p53-
dependent mechanism, and since b cells expressing the trans-
gene express p53, we next examined the functional significance114 Cell Metabolism 19, 109–121, January 7, 2014 ª2014 Elsevier Inc.of p53 in glucokinase-induced b cell
death. To accomplish this, we generated
mice in which activation of mutGCK in b
cells was coupled to Cre-mediated dele-
tion of p53 (Marino et al., 2000).Tomaximize the efficiency of recombination, we crossed insu-
lin-Cre mice with mutGCK mice. In the offspring (ins-GCK mice),
Cre-mediated recombination occurs in b cells during embryonic
development, immediately after the onset of insulin expression.
At day 16.5 of gestation, ins-mutGCK embryos had reduced
b cell area, and insulin+ cells stained frequently for gH2AX (Fig-
ure S4). At birth, transgenic mice were hyperglycemic (Figure 5A,
left), mildly hypoinsulinemic (Figure 5A, middle), and their insulin/
glucose ratio was lower than that of controls (Figure 5A, right).
b cell mass was reduced by >75% compared with controls (Fig-
ure 5B), and 80% of the mice died during the first week of life
(see below). These observations are consistent with those
described above for Pdx1-GCK mice. The more severe pheno-
type probably results from highly efficient recombination driven
by the insulin-Cre transgene and perhaps from an increased
sensitivity of newborn b cells to glucotoxic injury.
Loss of p53 in b cells (achieved by incorporation of loxP-
flanked p53 alleles, p53lox/lox) preserved islet architecture and
b cells in newborn ins-GCKmice (Figure 5C), suggesting preven-
tion of GCK-induced b cell death. However, ins-GCK;p53lox/lox
mice were only slightly less hyperglycemic than age-matched
Cell Metabolism
DNA Damage and p53 in b Cell Glucotoxicityins-GCK mice (which have normal p53) (Figure 5D). This finding
is expected because p53 deficiency can prevent cell death, but
does not interfere with upstream cell dysfunction. To determine if
p53 deficiency cell autonomously rescued transgene-express-
ing b cells, we stained for EGFP. In ins-GCK mice that survived
to 3 weeks of age, no EGFP+ cells were observed, suggesting
that cells strongly expressing the GCK mutation died and that
transgene-negative b cells took over. In contrast, at this age,
many islets of ins-GCK;p53lox/lox mice stained strongly for
EGFP, proving a cell-autonomous rescue of transgene-positive
b cells (Figure 5E). Finally, p53 deficiency in b cells increased
the chance of ins-GCK mice surviving postnatally: only 20% of
ins-GCK mice survived to 3 weeks of age, compared to 60%
of ins-GCK;p53lox/lox mice (Figure 5F).
These results suggest that p53 deficiency can prevent gluco-
toxic b cell death, but it does not interfere with upstream meta-
bolic processes that cause b cell dysfunction. In newborn
mice, the residual activity of surviving b cells appears to be suf-
ficient to keep most animals alive.
GLP-1 Treatment Prevents Both b Cell Death and
Dysfunction
We next attempted a pharmacological rescue of b cell function.
GLP-1 analogs alleviate both ER stress (Yusta et al., 2006) and
oxidative stress (Shimoda et al., 2011) in b cells. Liraglutide, a
GLP-1 receptor agonist and a T2D drug, was administered to
adult tamoxifen-injected Pdx1-GCK mice. At 4 days after trans-
gene induction, liraglutide-treated animals had no Chop+ GFP+
b cells (Figure 6A). The fraction of gH2AX+ b cells was reduced
(Figure 6B), as was b cell apoptosis (Figure 6C). In addition, lira-
glutide treatment neutralized the negative effect of mutant GCK
expression on b cell replication, observed 4 days after tamoxifen
injection (Figure 6D). Consistent with the reduction in b cell
apoptosis, mice treated with liraglutide for 9 days after tamoxifen
had more GFP+ cells compared with untreated littermates (Fig-
ure 6E). In contrast to the effect of p53 deficiency, liraglutide
treatment rescued b cell function. Pdx1-mutGCK mice treated
with liraglutide showed sustained hypoglycemia (Figure 6F), as
predicted. As expected from the known mechanism of action
of the drug, liraglutide did not cause hypoglycemia in control
animals.
DNA Damage and p53 Activity in Type 2 Diabetes
To determine if the mechanisms responsible for glycemic b cell
stress elucidated here are also operative in the context of chronic
hyperglycemia, we studied pancreatic specimens from diabetic
mice and humans.
db/db mice lack the leptin receptor and are hyperphagic,
obese, insulin resistant, and hyperglycemic. In 12-week-old
hyperglycemic db/db mice, 0.88% of b cells were positive for
gH2AX, compared with 0.07% in controls (Figure 7A). 53BP1
nuclear foci were seen in 9.2% of db/db b cells, compared
with 1.2% in controls (Figure 7B). Islets in db/db pancreata
also had cells (2.3%) that stained positively for p53, compared
with 0.4% in controls (Figure 7C), demonstrating a striking simi-
larity to b cells of Pdx1-mutGCK and ins-mutGCKmice. Further-
more, expression of the p53 target gene p21 (CIP1/WAF1) was
increased in b cells of db/db mice compared with controls, indi-
cating biological activity of p53 (Figure S5).CellFinally, we stained pancreatic sections from human cadaver
organ donors with T2D. Extensive 53BP1 foci were observed in
b cells from all four T2D donors examined, regardless of age or
disease duration (7.3% versus 1.1% of b cells in T2D and
controls, respectively) (Figure 7D and Table S1). Staining for
gH2AX and p53 was not seen (not shown). These findings sug-
gest that double-strand breaks in DNA and downstream activa-
tion of p53 may be a common feature of all forms of metabolic
b cell stress, whether caused by hyperactivity driven by specific
gene mutations, as in CHI, or by hyperglycemia, as in diabetes.
DISCUSSION
Double-Strand Breaks and p53 Activation in Glucotoxic
b Cell Failure
Our results identify a molecular pathway, conserved frommouse
to man, that mediates the toxic effects of glucose on pancreatic
b cells. We showed that increased glucose metabolism in b cells
causes double-strand breaks in DNA, likely accounting for acti-
vation of the p53 tumor suppressor and triggering b cell death.
This series of events is cell autonomous and triggered not by
hyperglycemia per se, but by the rate of intracellular glucose
metabolism. We also demonstrate that membrane depolariza-
tion via closure of KATP channels mediates the glucose-induced
DNA damage response and apoptosis, with involvement of
calcineurin signaling downstream. Experiments using inhibitors
of VDCCs failed to rescue glucotoxicity inmutGCK islets, making
it difficult to determine a role of these channels.
The identification of double-strand DNA breaks and p53 acti-
vation in b cells in both CHI and T2D suggests that a similar
mechanism operates in these seemingly opposite diseases,
regardless of whether excessive b cell activity is driven by muta-
tions in GCK or the KATP channel (as in CHI) or by chronic hyper-
glycemia (as in T2D). We propose that DNA double-strand
breaks and p53 are central players in glucose-induced b cell fail-
ure in both hyperinsulinism and T2D. Other evidence supporting
a link between DNA damage and b cell failure includes the
demonstration of diabetes in mice lacking the Werner syndrome
DNA helicase (Moore et al., 2008), an increased incidence of dia-
betes in individuals who received irradiation to the pancreas (de
Vathaire et al., 2012; Meacham et al., 2009), and identification of
oxidized DNA in islets of T2D patients (Sakuraba et al., 2002).
Analysis of islets from T2D patients previously identified an
increased expression of proteins in the p53 pathway (Nyblom
et al., 2009) and increased mRNA expression of the p53 target
p21 (Marselli et al., 2010). Like most cell types, b cells are sensi-
tive to activation of p53, as demonstrated by the development of
b cell failure in transgenicmice overexpressing a superactive p53
mutant (Hinault et al., 2011). We note, however, that the roles of
DNA double-strand breaks and p53 in the pathogenesis of T2D
remain unproven. It is also possible that the driver for DNA dam-
age in T2D is not excessive glycolysis as in CHI, given a report
that oxygen consumption is reduced rather than enhanced in
T2D islets in vitro (Doliba et al., 2012).
A potential caveat in this study is that both Pdx1-CreER and
insulin-Cre mice drive recombination in some non-b cells,
including the hypothalamus (in both lines), and in acinar cells,
duodenal cells, and delta cells (in Pdx1-CreER) (Wicksteed
et al., 2010). To rule out confounding effects of extra-isletMetabolism 19, 109–121, January 7, 2014 ª2014 Elsevier Inc. 115
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Figure 5. p53 Mediates GCK-Induced b Cell Toxicity
(A) Activation of mutGCK in b cells during embryonic development (ins-GCK) results in hyperglycemia (left), mild hypoinsulinemia (center), and decreased insulin/
glucose ratio (right; ratio 3 100) in postnatal day 3 mice. n = 24 control and 10 ins-GCK mice.
(B) Reduced b cell area in postnatal day 3 ins-GCK mice and representative images. Images were taken at 403magnification and stitched together to generate
high-resolution pictures of whole pancreatic sections (scale bar: 200 um). n = 3 mice/group. Insets show a higher magnification to better visualize insulin-stained
islets (scale bar: 100 um).
(C) b cell-specific p53 deletion preserves b cells and islet structure in postnatal day 3 ins-GCK mice. Green, insulin; red, glucagon + somatostatin.
(D) Blood glucose levels in newborn mice expressing the GCK mutation in b cells, with or without deletion of p53 (n > 3 mice/group).
(E) Expression of GFP in islets of 3-week-old ins-GCKmice, with (left) or without (right) codeletion of p53. NoGFP+ cells were seen in surviving ins-GCKmice. The
presence of GFP+ b cells in ins-GCK mice deficient for p53 demonstrates the cell-autonomous rescue of transgene-positive cells.
(legend continued on next page)
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Figure 6. Pharmacologic Rescue of GCK-
Induced b Cell Toxicity
Pdx1-GCK mice were treated twice a day with
liraglutide, starting 1 day after tamoxifen injection
until sacrifice at day 4 (A–D) or day 9 (E and F).
(A) Elimination of Chop in GFP+ b cells (left). n = 3–4
mice/group.
(B) Reduced gH2AX in b cells of Pdx1-GCK mice
treated with liraglutide. n = 3–4 mice/group.
(C) Reduced b cell apoptosis in b cells of Pdx1-GCK
mice treated with liraglutide. n = 4–6 mice/group.
(D) Rescued replication of GFP+ b cells in Pdx1-GCK
mice 4 days after injection of tamoxifen. Filled bars,
GFP b cells; hatched bars, GFP+ b cells represent-
ing cells expressing a high level of the GCK trans-
gene. n = 6–11 mice/group.
(E) Improved survival of b cells strongly expressing
GFP. Liraglutide was administered twice a day to
mice for 8 days, starting 1 day after tamoxifen
injection until sacrifice. n = 7–11 mice/group.
(F) Sustained hypoglycemia in Pdx1-GCK mice
treated with liraglutide. n = 7–11 mice/group. Blood
glucose levels of control mice and control mice
injected with liraglutide were not statistically
different. Pdx1-GCK mice injected with liraglutide
had significantly lower (p < 0.05) blood glucose levels
compared with Pdx1-GCK mice at days 2, 8, and 9.
Data are represented as mean ± SE.
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GCK mice 18 hr after tamoxifen administration and cultured
them in vitro. After 3 days of culture, Pdx1-GCK islets had
more gH2AX+ b cells than control islets (Figure S3), supporting
the cell-autonomous effect of GCK on b cell DNA damage. The
finding of DNA damage and b cell apoptosis in embryonic day
16.5 (E16.5) ins-GCK embryos (Figure S4) further indicates that
the key driver of b cell stress is intracellular glucose metabolism,
regardless of circulating glucose levels, which in the embryo are
controlled by the mother.
Signaling from Glucose to DNA Damage, p53 Activation,
and b Cell Death
Our experiments do not completely resolve the signaling path-
way leading from glucose metabolism to DNA damage and
b cell death. However, the finding that membrane depolarization
via KATP channels is both necessary and sufficient in this
pathway provides some clues. First, glucotoxicity is not a direct
consequence of excessive glycolysis or cellular energetics.
Indeed, b cells in KATP-CHI patients are exposed to chronic hy-(F) Ins-GCK mice at 3 weeks of age as a percentage of the total number of mice in the litter. When insulin-C
crossed, 50% of progeny are expected to contain both transgenes (black bar). On the wild-type p53 ba
6 litters and observed only 4 ins-GCKmice (binomial test, p < 0.0001). On the p53-deleted background (red
4 ins-GCK mice (binomial test, p = 0.3).
Data are represented as mean ± SE. See also Figure S4.
Cell Metabolism 19, 109–1poglycemia and so are expected to have
normal or reduced glycolysis. Our findings
are consistent with evidence that treatment
with KATP channel openers (forcing hyper-
polarization and causing b cell rest) protects
b cells against a number of toxic insults(Maedler et al., 2004; Ritzel et al., 2010), although in these
studies the roles of DNA damage and p53 were not recognized.
Our results are also in line with reports of increased apoptosis
and reduced b cell mass in mice lacking Kir6.2 (Miki et al., 2001).
Second, the importance of membrane depolarization sug-
gests (but does not prove) that calcium may be involved in
mediating glycolysis-induced DNA damage, p53 activation,
and apoptosis as previously suggested (Wang et al., 2011). Inter-
estingly, DNA damage and p53 activation are implicated in
neuronal excitotoxicity and degeneration (Miller et al., 2000;
Neema et al., 2005; Sakhi et al., 1994), and a recent study
showed that double-strand breaks form after normal neuronal
activity and are increased in a model of Alzheimer’s disease
(Suberbielle et al., 2013). We speculate that b cell glucotoxicity
is similar to neuronal excitotoxicity with respect to the crucial
role of calcium overload. It will be interesting to examine the rele-
vance for diabetes of pharmacologic approaches developed to
minimize neuronal damage after stroke (Greig et al., 2004). Phar-
macologic inhibition of calcineurin, a calcium-activated phos-
phatase, rescued b cell apoptosis in Pdx1-GCK mice. This isre+/ (heterozygous) and GCK homozygous mice are
ckground (blue bar), we obtained 39 adult mice from
bar), we obtained 11 mice from 7 litters and observed
21, January 7, 2014 ª2014 Elsevier Inc. 117
DBA C
Figure 7. b Cell DNA Double-Strand Breaks
and Activation of p53 in Type 2 Diabetes
(A) Staining for gH2AX and quantification in islets
of diabetic db/db mice. Control mice were age-
matched wild-typemice. n = 3 db/db and 4 control
mice. Arrows point to gH2AX+ b cells.
(B) Staining for 53BP1 in islets of diabetic db/db
mice and quantification. n = 3 db/db and 6 control
mice. Arrows point to b cells with nuclear 53BP1+
foci. Bars represent the percentage of b cells
containing at least one 53BP1+ nuclear focus.
(C) Staining for p53 and quantification in islets of
diabetic db/db mice. n = 5 db/db and 3 control
mice.
(D) Staining and quantification of 53BP1 nuclear
foci in pancreatic sections of human organ donors
with or without T2D. n = 4/group.
Data are represented as mean ± SE. See also
Figure S5 and Table S1.
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tors (Nito et al., 2011) and further underscores the similarity
between b cell glucotoxicity and neuronal excitotoxicity. Further
experiments are needed to pinpoint the signaling events leading
from KATP channel closure to DNA damage and, consequently or
independently, to b cell apoptosis.
Similarity between Type 2 Diabetes and Congenital
Hyperinsulinism
While T2D and CHI present with opposite glycemia phenotypes,
our results suggest that these diseases share some pathogenic
mechanisms. In both, b cells initially respond to increased glycol-
ysis or membrane depolarization by enhanced insulin secretion
and replication. This allows the maintenance of euglycemia in
insulin-resistant prediabetics and causes pathologic hypoglyce-
mia in CHI patients. At later stages, b cell glucotoxicity becomes
dominant, at least in part via the molecular pathway discussed
above. The ensuing b cell failure causes hyperglycemia in T2D,
and the normalization of glycemia followed by hyperglycemia,118 Cell Metabolism 19, 109–121, January 7, 2014 ª2014 Elsevier Inc.in CHI. The latter is clearly seen in the
Pdx1-GCK mouse model. In the case of
KATP-CHI, patients who do not undergo
pancreatectomy eventually enter clinical
remission, whereas those who do un-
dergo partial pancreatectomy develop
insulin-requiring diabetes, often many
years after surgery (Beltrand et al.,
2012; Huopio et al., 2003; Leibowitz
et al., 1995). In the case of GCK-CHI,
we showed here b cell apoptosis as well
as long-term remission and progression
to diabetes in multiple cases. We note
the striking differences in timing of dis-
ease progression, which mask the quali-
tative similarity: human T2D typically
develops over decades, and diabetes
from GCK-CHI also occurs only late in
life, while Pdx1-GCK mice switch from
hypoglycemia to b cell failure in just afew days. The latter likely reflects distinct technical aspects of
the transgenic system, e.g., the presence of three GCK alleles
and expression of mutant GCK from an ectopic promoter not
responding to glucose.
Glucose-Induced b Cell Replication versus Death
More work is required to identify where the glycolysis-mediated
mitogenic and toxic pathways diverge and the reason for domi-
nance of one outcome over the other. From a therapeutic
perspective, an outstanding question is whether small-mole-
cule glucokinase activators (GKA), shown to increase insulin
secretion and b cell replication (Nakamura et al., 2009; Porat
et al., 2011; Shirakawa et al., 2013), may also be toxic to
b cells. The latter is suggested by the inability of GKA to
increase b cell mass (Nakamura et al., 2009, 2012) and the
transient benefit reported in clinical trials (Kiyosue et al.,
2013; Meininger et al., 2011; Wilding et al., 2013). It will also
be important to determine the primary stress impacting b cells,
as this may have clinical implications (for example, regarding
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(Guo et al., 2013). Nonetheless, our current data suggest
that the mitogenic and toxic effects of glucose on b cells
can in principle be uncoupled pharmacologically (in our case,
using a GLP-1 angonist), providing a positive outlook for
regenerative therapy in diabetes. Combined treatment with
GKA and GLP-1 analogs (Nakamura et al., 2012) may be a first
step toward productive, nontoxic, glycolysis-induced b cell
replication.
EXPERIMENTAL PROCEDURES
Mice
To generate mutGCK mice, the Y214C GCK mutation was introduced into rat
GCK cDNA (a gift from Donald K. Scott) and cloned upstream of IRES-EGFP
and downstream of a loxP-flanked stop cassette in a plasmid containing
Rosa26 homology arms (Murtaugh et al., 2003; Srinivas et al., 2001). After
sequence validation, the plasmid was electroporated into ESCs, and colonies
were screened for homologous recombination. Targeted cells were injected to
C57BL/6 blastocysts, and resulting chimeraswere bred for germline transgene
transmission.
Blood glucose was measured as described (Nir et al., 2007). Serum insulin
was measured using an ELISA kit (Crystal Chem) after overnight fasting (adult
mice, Figure 1) or without fasting (postnatal day 3 pups, Figure 5). Liraglutide
(Novo Nordisk) was dissolved in saline, and 100 ug/kg was injected subcuta-
neously twice per day (compared with injection of saline). Tamoxifen (Sigma)
was dissolved in corn oil (Sigma) to 20 mg/ml, and 8 mg was injected subcu-
taneously at days 0 and 2. For in vitro experiments (Figure S3), tamoxifen was
injected once. Tacrolimus (FK-506) (Prograf; Astellas) was dissolved in phos-
phate-buffered saline (PBS) to 0.1 mg/ml, and 1 mg/kg was injected intraper-
itoneally daily from day 1 after tamoxifen administration. Nifedipine (Sigma)
was freshly dissolved in 5% DMSO, 1% polysorbate 80, and 94% saline to
1 mg/ml, and 10 mg/kg was injected intraperitoneally twice per day, or added
to cultured islets (10 mM).
As controls for mice expressing mutant GCK, we used single transgenic
littermates, which were identical to wild-type in terms of stress marker expres-
sion and b cell apoptosis (not shown).
Islets were isolated following collagenase perfusion and handpicked as
described (Porat et al., 2011).
The joint HebrewUniversity and HadassahMedical Center ethics committee
(IACUC) approved the study protocol for animal welfare. The Hebrew Univer-
sity is AAALAC accredited.
Human Material
For the data presented in Figure 7, we used paraffin sections obtained from
pancreata of brain-dead patients after Institutional Review Board (IRB)
approval. Maximal warm ischemia time before fixation was 6 hr. Patient details
are presented in Table S1.
Material from GCK-CHI and KATP-CHI patients (Figures 4 and S1) was
obtained after pancreatectomy as described (Kassem et al., 2000, 2010;
Sayed et al., 2009; Snider et al., 2013). Age-matched controls shown in
Figure S1 were obtained from the Network for Pancreatic Organ Donors
(nPOD).
Histology and Immunostaining
Tissue processing was performed as described (Nir et al., 2007) using
antibodies listed in Table S2. TUNEL staining was performed using a kit
(In Situ Cell Death Detection Kit, AP; Roche). Fluorescent images were taken
on a Nikon C1 confocal microscope at 4003 magnification.
For b cell area determination, consecutive paraffin sections 75 mm apart,
spanning the entire pancreas, were stained for insulin and hematoxylin. Digital
403 images were obtained, stitched together using NIS-Elements software,
and the fraction of tissue stained for insulin was determined.
For in vitro staining, islets were trypsinized and cytospun at 14,000 rpm for
5 min. Slides were fixed for 10 min with paraformaldehyde, permeabilized for
15 min, and then stained for insulin and gH2AX.CellOxygen Consumption
Oxygen consumption rate was measured using a Seahorse XF24 (Seahorse
Bioscience). Islets were isolated from control or mutGCK mice 2 days after
tamoxifen injection and incubated overnight at 5.5 mM glucose. Pools of
Pdx1-GCK and control islets were divided into groups of sixty islets and plated
in Seahorse XF24 Islet Capture Microplates. Basal respiration at 2mMglucose
was measured. Low glucose levels were selected to optimally observe the
activity of mutant GCK, which has a lower KM to glucose than wild-type
GCK. Values were normalized to islet area (images of islets taken after oxygen
measurements) and analyzed by Seahorse software.
RT-PCR
Islets were isolated from Pdx1-GCK mice 2 days (for replication markers) or
3 days (for stress markers) after tamoxifen injection. Total RNA was isolated,
and cDNA synthesis was performed using random primers (Roche) and
reverse transcriptase (ImProm-II; Promega). For quantitative real-time PCR,
we used SYBR Green Master Mix in the 7900HT instrument in triplicate
(Applied Biosystems). The relative amount of mRNA was calculated using
comparative CT method after normalization to b-actin. PCR primers are
described in Table S3.
Statistical Analyses
In all graphs, *p < 0.05; **p < 0.01; ***p < 0.005; NS, p > 0.05 by Student’s t test,
unless otherwise stated (Figure 5F). Data are represented as mean ± SE.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and three tables and can be
found with this article online at http://dx.doi.org/10.1016/j.cmet.2013.11.007.
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